Incyte News and Activities

Presence

Incyte is a biotechnology company that develops and sells medicines for cancer and inflammatory diseases. Its products and research services support patients, healthcare providers, and research partners.

Incyte products and services overview:

Cancer medicines
Inflammation treatments
Rare disease therapies
Drug discovery
Clinical development
Biologic therapies

Revenue: ~$4 billion

Employees: 2,600

Headquarters: Wilmington, United States (USA)

Incyte is one of the...

Incyte is a company listed under the stock ticker INCY (US).

Incyte has a direct presence in 3 countries.

Incyte has 4 subsidiaries including Escient Pharmaceuticals, Incyte Canada and Incyte Europe.

They are in:

Biotechnology80%
Pharmaceuticals20%

Acquisition, funding and merger involving Incyte.

Incyte has announced the acquisition of Star Therapeutics (posted on June 9 2026).
Vor Biopharma and Incyte have announced they will merge (posted on June 30 2025)..

Executives

View the org chart displaying its 75 main executives

Most searched biographies at Incyte

Popular executive movements at Incyte

Suketu Upadhyay will join the company as Chief Financial Officer on May 4, 2026 (posted on April 28 2026).
Thomas Tray, Principal Financial Officer, will leave the company on May 4, 2026 (posted on April 28 2026).
Sri Ghatta has joined the company as Senior Director, Clinical Research (posted on April 9 2026).

Click here to view some more movements at Incyte

Create your alert
to follow the executive moves at Incyte.